TY - JOUR
T1 - Chronic Spinal Cord Injury Regeneration with Combined Therapy Comprising Neural Stem/Progenitor Cell Transplantation, Rehabilitation, and Semaphorin 3A Inhibitor
AU - Yoshida, Takashi
AU - Tashiro, Syoichi
AU - Nagoshi, Narihito
AU - Shinozaki, Munehisa
AU - Shibata, Takahiro
AU - Inoue, Mitsuhiro
AU - Ogawa, Shoji
AU - Shibata, Shinsuke
AU - Tsuji, Tetsuya
AU - Okano, Hideyuki
AU - Nakamura, Masaya
N1 - Publisher Copyright:
© 2024, Society for Neuroscience. All rights reserved.
PY - 2024
Y1 - 2024
N2 - Spinal cord injury (SCI) often results in various long-term sequelae, and chronically injured spinal cords exhibit a refractory feature, showing a limited response to cell transplantation therapies. To our knowl-edge, no preclinical studies have reported a treatment approach with results surpassing those of treatment comprising rehabilitation alone. In this study of rats with SCI, we propose a novel combined therapy involving a semaphorin 3A inhibitor (Sema3Ai), which enhances axonal regeneration, as the third treatment element in combination with neural stem/progenitor cell transplantation and rehabili-tation. This comprehensive therapeutic strategy achieved significant improvements in host-derived neuronal and oligodendrocyte differentiation at the SCI epicenter and promoted axonal regeneration even in the chronically injured spinal cord. The elongated axons established functional electrical con-nections, contributing to significant enhancements in locomotor mobility when compared with animals treated with transplantation and rehabilitation. As a result, our combined transplantation, Sema3Ai, and rehabilitation treatment have the potential to serve as a critical step forward for chronic SCI patients, improving their ability to regain motor function.
AB - Spinal cord injury (SCI) often results in various long-term sequelae, and chronically injured spinal cords exhibit a refractory feature, showing a limited response to cell transplantation therapies. To our knowl-edge, no preclinical studies have reported a treatment approach with results surpassing those of treatment comprising rehabilitation alone. In this study of rats with SCI, we propose a novel combined therapy involving a semaphorin 3A inhibitor (Sema3Ai), which enhances axonal regeneration, as the third treatment element in combination with neural stem/progenitor cell transplantation and rehabili-tation. This comprehensive therapeutic strategy achieved significant improvements in host-derived neuronal and oligodendrocyte differentiation at the SCI epicenter and promoted axonal regeneration even in the chronically injured spinal cord. The elongated axons established functional electrical con-nections, contributing to significant enhancements in locomotor mobility when compared with animals treated with transplantation and rehabilitation. As a result, our combined transplantation, Sema3Ai, and rehabilitation treatment have the potential to serve as a critical step forward for chronic SCI patients, improving their ability to regain motor function.
KW - axon regeneration
KW - cell transplantation
KW - chronic phase spinal cord injury
KW - rodent
KW - semaphorin 3A inhibitor
KW - treadmill training
UR - http://www.scopus.com/inward/record.url?scp=85184864186&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85184864186&partnerID=8YFLogxK
U2 - 10.1523/ENEURO.0378-23.2024
DO - 10.1523/ENEURO.0378-23.2024
M3 - Article
C2 - 38262737
AN - SCOPUS:85184864186
SN - 2373-2822
VL - 11
JO - eNeuro
JF - eNeuro
IS - 2
M1 - ENEURO.0378-23.2024
ER -